Danaher Corporation (DHR)vsIDEXX Laboratories Inc (IDXX)
DHR
Danaher Corporation
$230.08
+0.94%
HEALTHCARE · Cap: $163.25B
IDXX
IDEXX Laboratories Inc
$672.04
+0.06%
HEALTHCARE · Cap: $44.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 462% more annual revenue ($25.61B vs $4.55B). IDXX leads profitability with a 25.0% profit margin vs 16.9%. DHR appears more attractively valued with a PEG of 1.32. DHR earns a higher WallStSmart Score of 65/100 (B-).
DHR
Strong Buy65
out of 100
Grade: B-
IDXX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DHR.
Margin of Safety
-48.6%
Fair Value
$436.51
Current Price
$672.04
$235.53 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.1%
Earnings expanding 37.8% YoY
Generating 1.6B in free cash flow
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 32.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Operating Margin, EPS Growth. Profitability is solid with margins at 16.9% and operating margin at 21.1%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Key Dynamics to Monitor
IDXX carries more volatility with a beta of 1.55 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
DHR generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (65/100 vs 61/100), backed by strong 16.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?